Thought of the day:
- Frequency Therapeutics patents / pending patents for FX-322 include claims that the drug causes "progenitor cell activation" by causing an LGR5+ (progenitor) support cell to divide and produce a "hair cell" and "an LGR5+ support cell"
- They also separately claim that LGR5+ cells can just create more support cells.
Frequency Therapeutics has claimed that the population of new hair cells is 'self-limited' from Progenitor Cell Activation. Meaning, that FX-322 cannot create a greater population of hair cells than originally existed.
What they have not discussed, in reference to bullet #2, is whether progenitors can create more support cells than needed. Could this mean that progenitors could copy themselves, and 'fill gaps' where LGR5+ cells are missing entirely?